Fear of cancer may have unwanted effect on public screening uptake
the ONA take:
People who worry about developing cancer are more likely to want to undergo screening for colon cancer; however, according to new research from the Cancer Research UK Health Behaviour Research Centre at UCL, that fear makes them less likely to actually go for the test.
Research to date has used a combined measure of cancer fear, which does not explain how fear results in such different actions. In this study, the researchers distinguished different aspects of fear to see whether it had different effects on people’s decisions about cancer screening.
Approximately 2,000 participants were randomized to receive a screening invitation. Clinical records show that 71% actually attended; 68% of those who reported feeling uncomfortable thinking about cancer attended screening, compared with 77% of those who did not feel uncomfortable.
The research findings suggest that public service announcements about colon cancer screening need to focus more on the preventive value of screening than increasing public fear of cancer.
People who worry about developing cancer are more likely to want to undergo screening for colon cancer.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|